- Corporate Officers - C
- Colonnese Mark P
Insider Trading History of Colonnese Mark P
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Colonnese Mark P since 2005.
The trader's CIK number is 1040766.
At the time of the last reporting, Colonnese Mark P was the Exec VP, Commercial of Vaxart, Inc.. (stock ticker symbol VXRT).
Also see all insider trading activities at Vaxart, Inc..
Note that in the past
COLONNESE MARK P also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Vaxart, Inc. (BOTA) by Colonnese Mark P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2016 | BOTA | 7,000 | $9,814 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Atherogenics Inc (AGIX) by Colonnese Mark P
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2007 | AGIX | 0 | $0 | 0 | $0 | 25,000 | $9,500 |
| 2005 | AGIX | 0 | $0 | 100,000 | $2,135,000 | 100,000 | $33,000 |
Insider trading activities at 2 companies by Colonnese Mark P:
1. Vaxart, Inc. (BOTA)
2. Atherogenics Inc (AGIX)
Table 1. Insider trading of Vaxart, Inc. (BOTA) by Colonnese Mark P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2016-02-09 | BOTA | Buy | 7,000 | 1.40 | 9,814 |
Table 2. Insider trading of Atherogenics Inc (AGIX) by Colonnese Mark P
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2007-03-20 | AGIX | Option Ex | 25,000 | .38 | 9,500 |
| 2005-12-27 | AGIX | Sale | 100,000 | 21.35 | 2,135,000 |
| 2005-12-27 | AGIX | Option Ex | 100,000 | .33 | 33,000 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Colonnese Mark P
(Exec VP, Commercial of Vaxart, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.